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Intracellular trafﬁcking of cargoes is an essential process tomaintain the structure and function of all mammalian
cell types, but especially of neurons because of their extreme axon/dendrite polarisation. Axonal transport medi-
ates the movement of cargoes such as proteins, mRNA, lipids, membrane-bound vesicles and organelles that are
mostly synthesised in the cell body and in doing so is responsible for their correct spatiotemporal distribution in
the axon, for example at specialised sites such as nodes of Ranvier and synaptic terminals. In addition, axonal
transport maintains the essential long-distance communication between the cell body and synaptic terminals
that allows neurons to react to their surroundings via trafﬁcking of for example signalling endosomes.
Axonal transport defects are a common observation in a variety of neurodegenerative diseases, andmutations in
components of the axonal transport machinery have unequivocally shown that impaired axonal transport can
cause neurodegeneration (reviewed in El-Kadi et al., 2007, De Vos et al., 2008; Millecamps and Julien, 2013).
Here we review our current understanding of axonal transport defects and the role they play in motor neuron
diseases (MNDs) with a speciﬁc focus on the most common form of MND, amyotrophic lateral sclerosis (ALS).










1. Microtubule-based axonal transport
Traditionally two main classes of axonal transport are distinguished
based on the overall speed of movement, namely fast axonal transport
(~50–400 mm/day or 0.6–5 μm/s) and slow axonal transport (0.2–
10 mm/day or 0.0002–0.1 μm/s). Slow axonal transport is further
subdivided into slow component a (SCa) and b (SCb) based on the pro-
teins transported and the speed, 0.2–3 and 2–10 mm/day, respectively.
We now know that both fast and slow axonal transport is mediated by
the samemolecularmotors that move cargoes alongmicrotubules, with
the differences in overall speed caused by prolonged pauses between
movement phases in slow axonal transport (reviewed in Black, 2016).
Microtubules are polymers made up of tubulin which itself is a het-
erodimer ofα-tubulin andβ-tubulin.Microtubules are rigid hollow rods
of approximately 25 nm in diameter built from 13 linear protoﬁlaments
composed of alternating tubulin heterodimers and arranged around a
hollow core. Due to the head to tail arrangement of the tubulin hetero-
dimers microtubules are polarised with a fast growing plus end and a
slow growing minus end. The polarity of microtubules dictates the di-
rection of movement of the molecular motors along them.
There are two major families of microtubule based molecular mo-
tors, namely the kinesin family which move mostly toward the plus
end of microtubules and the cytoplasmic dyneins that move toward
the minus end (reviewed in Hirokawa et al., 2010). Because axonal mi-
crotubules are uniformly orientated with their plus end pointing away
from the cell body (Baas et al., 1988) kinesins mediate anterograde
transport away from the cell body toward the axon terminal and cyto-
plasmic dynein drives retrograde transport from the distal axon toward
the cell body.
The human kinesin superfamily contains 45 members, subdivided
into 15 subfamilies. The main kinesin family members involved in fast
axonal transport are kinesin-1 (previously referred to as conventional
kinesin or KIF5), and the kinesin-3 family members KIF1A, KIF1Bα and
KIF1Bβ. Anterograde slow axonal transport appears to be mainly medi-
ated by kinesin-1 (Xia et al., 2003). Kinesin-1 is a heterotetramer
consisting of two kinesin heavy chains (KHCs) and two kinesin light
chains (KLCs). KHC contains the catalytic motor domain, a neck linker
region, an α-helical stalk interrupted by two hinge regions, and the
tail. The motor domain binds microtubules and hydrolyses ATP to gen-
erate force. Together with the neck region, the motor domain conveys
processivity and direction of movement. The stalk is required for
dimerisation and the tail, together with KLC is involved in regulation
of motor activity as well as cargo binding (reviewed in Hirokawa et
al., 2010). The latter also involves various adapter proteins such as c-
Jun N-terminal kinase (JNK)-interacting protein (JIP) 1, 3 and 4,
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mitochondrial Rho GTPase (Miro) 1 and 2, trafﬁcking kinesin (TRAK) 1
and 2, and huntingtin that link kinesin-1 to speciﬁc cargo, directly or
via KLCs (reviewed in Fu and Holzbaur, 2014). In contrast to kinesin-1,
KIF1A and KIF1Bα/β are monomeric kinesin motors consisting of an
N-terminal motor domain, a conserved stalk domain and a C-terminal
pleckstrin homology (PH) that aids in the interaction with cargoes in
conjunction with adapter proteins such as DENN/MADD (Differentially
Expressed In Normal And Neoplastic Cells/MAP Kinase Activating
Death Domain) (Niwa et al., 2008). Kinesin-1 transports a number of
different fast axonal transport cargoes includingmitochondria and a va-
riety of vesicular and non-vesicular cargoes such as lysosomes, signal-
ling endosomes (e.g. brain-derived neurotrophic factor (BDNF)
and tropomyosin receptor kinase (Trk) B (TrkB) vesicles), amyloid pre-
cursor protein (APP) vesicles, AMPA vesicles, and mRNA/protein
complexes. Kinesin-1 also mediates the slow axonal transport of cyto-
skeletal cargoes such as microtubules and neuroﬁlaments (reviewed
in Hirokawa et al., 2010). KIF1A and KIF1Bβmotors transport synaptic
vesicle precursors (Okada et al., 1995), signalling endosomes such as
TrkA vesicles (Tanaka et al., 2016), and the autophagy protein ATG9
(Stavoe et al., 2016). KIF1Bα has also been proposed to drive antero-
grade transport of mitochondria (Nangaku et al., 1994).
In contrast to themultiple kinesins that drive anterograde transport,
retrograde transport is almost exclusively mediated by a single cyto-
plasmic dynein. Cytoplasmic dyneins are members of the ATPases asso-
ciatedwith diverse cellular activities (AAA+) family of ATPase proteins.
They are sub-divided into cytoplasmic dynein 1 and 2,with cytoplasmic
dynein 1 being the main retrograde molecular motor in neurons. Cyto-
plasmic dynein 1 (hereafter referred to as dynein) is composed of two
homodimerised dynein heavy chains (DHCs) andmultiple dynein inter-
mediate (DIC), dynein light intermediate (DLIC), and light chains (LC)
(reviewed in King, 2012). The assembly of these polypeptides forms a
~1.5 MDa protein complex whose functions, cargo binding and
localisation are regulated by adapter complexes including dynactin,
Bicaudal D2 (BICD2), lissencephaly 1 (LIS1), nuclear distribution protein
(NUDE or NDE) and NUDE-like (NUDEL or NDEL). The ~1MDa dynactin
complex contains p150Glued which interacts with a short actin-like
Arp1 ﬁlament and various additional dynactin subunits including p50/
dynamitin, p62, CapZ, p27, p25, and p24. p150Glued associates with dy-
nein via the DICs and also directly binds to microtubules; through its
cargo-binding domain p150Glued binds a number of vesicular cargo
adapters, including sorting nexin 6 (SNX6), huntingtin-associated pro-
tein 1 (HAP1) and JIP1 (reviewed in Kardon and Vale, 2009; Fu and
Holzbaur, 2014).
2. Axonal transport defects in ALS
ALS, the most common form of MND, is an adult onset and progres-
sive neurodegenerative disorder caused by selective injury and death of
upper motor neurons in the motor cortex and lower motor neurons in
the brain stem and spinal cord. Degeneration of motor neurons leads
to progressive muscle wasting followed by paralysis and usually culmi-
nates in death through respiratory failure. ALS has an incidence of 2 per
100,000 and amean age of onset of 55–65 years. The average survival is
approximately 3 years from symptom onset (reviewed in Kiernan et al.,
2011). An estimated 10% of ALS is inherited, usually in an autosomal
dominant fashion (familial ALS), but most ALS cases have no clear ge-
netic basis and occur seemingly random in the population (sporadic
ALS). Several genes have been associatedwith familial ALS, including su-
peroxide dismutase 1 (SOD1) (~12% of familial cases), TAR DNA binding
protein (TARDBP; TDP-43) (~4%), Fused in sarcoma (FUS) (~4%), and
C9orf72 (~40%) (reviewed in Renton et al., 2014). The causes of motor
neuron degeneration appearmultifactorial. From researchmostly on fa-
milial ALS cases and animal models a number of possible pathogenic
mechanisms underlying motor neuron degeneration have emerged in-
cluding oxidative stress, mitochondrial dysfunction, misfolded protein
toxicity/autophagy defects, RNA toxicity, excitotoxicity, and defective
axonal transport (reviewed in Ferraiuolo et al., 2011; De Vos et al.,
2008; Millecamps and Julien, 2013).
2.1. Axonal pathology
Early evidence for axonal transport defects in ALS came from
electron microscopy and neuropathological studies of post-mortem
ALS cases that revealed abnormal accumulations of phosphorylated
neuroﬁlaments (a pathological hallmark of ALS), mitochondria and
lysosomes in the proximal axon of large motor neurons (Okada et
al., 1995; Hirano et al., 1984b; Hirano et al., 1984a; Rouleau et al.,
1996) and axonal spheroids containing a variety of vesicles, lyso-
somes, and mitochondria as well as neuroﬁlaments and microtu-
bules (Sasaki and Iwata, 1996; Corbo and Hays, 1992) (Fig. 1).
Consistent with damage to the axonal transport machinery as an un-
derlying cause, hyperphosphorylated neuroﬁlament heavy polypep-
tide (NF-H) positive spheroids stained strongly for KHC but,
interestingly, not dynein (Toyoshima et al., 1998).
Direct evidence for axonal transport defects in ALSwas obtained fol-
lowing the development of mutant SOD1 transgenic mouse strains as
mammalian animal models of ALS. Sciatic nerve ligation in SOD1G93A
transgenic mice revealed a signiﬁcant reduction of immune-reactive
kinesin-1 on the proximal side of the ligation in both younger asymp-
tomatic and older presymptomatic transgenic mice whereas a marked
reduction in dynein immunoreactivity was apparent only in the pre-
symptomatic mice (Warita et al., 1999). Both defects correlated with
signiﬁcant spinal motor neuron loss, reducedmyelinated ﬁbre densities
in the sciatic nerve, and muscle pathology (Warita et al., 1999). Meta-
bolic labelling experiments revealed a signiﬁcant reduction in the
slow anterograde transport of cytoskeletal components months before
the onset of neurodegeneration in SOD1G37R transgenic mice
(Williamson and Cleveland, 1999) while both slow and fast axonal
transport were found to be impaired in SOD1G93A transgenic mice
(Zhang et al., 1997).
2.2. Endosome trafﬁcking and retrograde signalling
Detailed analysis of axonal transport of speciﬁc cargoes in primary
neurons and in vivo further conﬁrmed these early studies. Time-lapse
recording of a ﬂuorescently labelled fragment of the tetanus toxin
TeNT HC which is transported in the same compartment as
neurotrophins, revealed defective dynein-mediated retrograde trans-
port in motor neurons isolated from SOD1G93A transgenic embryos
(Kieran et al., 2005) and in vivo in the intact sciatic nerve of presymp-
tomatic SOD1G93A transgenic mice (Bilsland et al., 2010). Further evi-
dence for the involvement of perturbed dynein-mediated retrograde
axonal transport was provided by examining the transport of a
neurotracer to the soma of spinal motor neurons following its injection
to the gastrocnemius muscle in SOD1G93A transgenic mice. This inves-
tigation demonstrated a signiﬁcant reduction in retrograde axonal
transport, which temporally correlated with disease progression
(Ligon et al., 2005). Similarly, direct time-lapse recordings of ﬂuores-
cently labelled TrkB vesicles revealed defective retrograde transport in
SOD1G93A expressing neurons (Bilsland et al., 2010). Interestingly, mu-
tations in alsin (ALS2),which cause juvenile-onset ALS, disturb its Rab5-
GEF activity and consequently disrupt Rab5-dependent endosome traf-
ﬁcking and AMPA receptor trafﬁcking (Hadano et al., 2006; Lai et al.,
2006; Devon et al., 2006; Lai et al., 2009). Since retrograde neurotrophin
trafﬁcking requires Rab5 activity (Deinhardt et al., 2006) alsin muta-
tionsmay thus cause neurodegeneration by inhibition of retrograde ax-
onal transport. Along the same lines it has been shown that ALSmutant
chargedmultivesicular body protein 2B (CHMP2B) impairs recruitment
of Rab7 to endosomes (Urwin et al., 2010). BecauseRab7 is also required
for retrograde neurotrophin signalling (Deinhardt et al., 2006),
disrupted retrograde trafﬁckingmay explain the neuronal inclusion for-
mation and axonal degeneration in mutant CHMP2B transgenic mice
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(Ghazi-Noori et al., 2012). In contrast to the retrograde-speciﬁc inhibi-
tion of axonal transport of TrkB signalling endosomes, time-lapse re-
cording of EGFP-APP labelled vesicles revealed reduced transport in
both anterograde and retrograde directions in mutant SOD1G93A,
A4V, G85R or G37R transfected cortical neurons (De Vos et al., 2007).
Nevertheless, this data indicates a possible role for disrupted retrograde
signalling in ALS.
2.3. Mitochondrial trafﬁcking
Live microscopy revealed reduced anterograde but not retrograde
axonal transport of ﬂuorescently labelled mitochondria in cultured cor-
tical neurons expressing ALS mutant SOD1G93A, A4V, G85R or G37R
and in embryonic motor neurons expressing SOD1G93A (De Vos et al.,
2007). This defect was later conﬁrmed in vivo by time-lapse measure-
ments in single axons in the intact sciatic nerve of presymptomatic
SOD1G93A transgenic mice (Bilsland et al., 2010; Magrané et al.,
2014) and rats (Magrané et al., 2012). In cultured neurons, the transport
deﬁcit resulted in depletion of mitochondria from axons and a concom-
itant increase in inter-mitochondrial distance (De Vos et al., 2007).
In vivo in motor neurons of early symptomatic SOD1G37R and
SOD1G85R transgenicmice the number of axonal mitochondria was re-
duced and their distribution was no longer homogeneous throughout
the axon (Vande Velde et al., 2011) and in SOD1G93A transgenic mice
mitochondria were found in abnormal clusters along the axon
(Magrané et al., 2014). Likewise, reduced axonal transport correlated
with decreased mitochondrial density in the motor axons of
SOD1G93A transgenic rats (Magrané et al., 2012).
One group reported axonal transport defects in wild type SOD1
transgenic mice that show no neurodegeneration, and no axonal
transport defects in SOD1G85R transgenic mice (Marinkovic et al.,
2012). However, compared to SOD1G93A transgenic mice the onset
of the transport defect is later in wild type SOD1 transgenic mice,
2 months after birth in wild type SOD1 transgenic mice compared
to postnatal day 20 in SOD1G93A transgenic mice, and only reaches
levels comparable to SOD1G93A at 4 months of age (Marinkovic et
al., 2012). It has been reported that wild type SOD1 transgenic mice
exhibit signs of premature aging (Avraham et al., 1991; Avraham et
al., 1988). Thus, it is possible that the late transport defect in wild
type SOD1 transgenic mice is linked to the reductions in transport
that have been observed in aging mice (Milde et al., 2015). The lack
of axonal transport defects in SOD1G85R transgenic mice is in con-
trast with the reduction in the number of axonal mitochondria and
the skewed distribution of mitochondria observed by others
(Vande Velde et al., 2011), but may be due to the fact that unlike
other mutant SOD1 transgenic mice the SOD1G85R transgenic mice
only express low levels of the unstable SOD1G85R protein and the
mice tend to remain healthy for most of their lifespan, only
succumbing to the disease approximately one week before death
(Bruijn et al., 1997).
Fig. 1. Axonal transport defects in ALS and underlying mechanisms. The axonal transport of various organelles has been shown to be defective in a number of ALS models and in ALS
patients (a–g). A number of proposed molecular mechanisms underlying defective transport are indicated (1–6). See text for details.
(Figure adapted with permission from Annual Review of Neuroscience, Vol. 31, De Vos, K. J., Grierson, A. J., Ackerley, S., and Miller, C. C., Role of axonal transport in neurodegenerative
diseases, p151–173, Copyright © 2008 by Annual Reviews.)
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Defects in mitochondrial transport are not limited to SOD1-related
ALS. Overexpression of the ALS mutant vesicle-associated membrane
protein-associated protein B (VAPB) VAPBP56S caused a selective
block in anterograde transport of mitochondria (Morotz et al., 2012).
Similarly, overexpression of wild-type TDP-43 and to a greater extent
ALS mutant TDP-43Q331K or M337V reduced mitochondrial transport
and mitochondrial density in primary motor neurons (Wang et al.,
2013). Disruption of axonal mitochondrial transport was also observed
in vivo in ALS mutant TDP-43A315T transgenic mice (Magrané et al.,
2014) andwild-type TDP-43 andmutant TDP-43M337Voverexpressing
mice exhibitedmitochondrial aggregation consistentwith transport de-
fects (Xu et al., 2011; Xu et al., 2010). It has to be noted that in contrast
to these studies, Alami et al. did not ﬁnd disruption of axonal transport
of mitochondria in cortical neurons expressing wild type or mutant
TDP-43M337V or A315T at 5–7 days in culture (Alami et al., 2014).
Moreover, expression ofwild type or TDP-43M337Vdid not affectmito-
chondrial transport in Drosophila motor axons, although in the same
study TDP-43M337V did reduce the KIF1A-dependent motility of
dense-core vesicles visualised using NPY-GFP (Baldwin et al., 2016).
Possibly, different model systems, neuronal types, and experimental
conditions may explain these opposing results.
Expression of either wild type human FUS or the ALS-associated
FUS-P525L mutant in Drosophilamotor neurons reduced both motility
and processivity of mitochondrial axonal transport (Chen et al., 2016)
but this was not observed by others (Baldwin et al., 2016). Interestingly
Baldwin et al. did ﬁnd that expression the ﬂy homolog of FUS, cabeza
(caz) and cazP398L, a pathogenic equivalent of human FUS-P525L,
inhibited mitochondrial transport (Baldwin et al., 2016). The same au-
thors explored the effects of transgenic expression of C9orf72 GGGGCC
(G4C2) repeat expansion constructs on axonal transport and found that
a non-pathogenic repeat length (G4C2-3) had no effect onmitochondri-
al transport while expression of 36 repeats (G4C2-36) which were pre-
viously shown to cause neurotoxicity in thismodel, caused a decrease in
the number of motile mitochondria (Baldwin et al., 2016). The glycine-
alanine (GA) dipeptide repeat protein (DPR) produced by repeat-asso-
ciated non-ATG (RAN) translation of the pathogenic C9orf72 GGGGCC
expanded repeats has been shown to interact with Unc119, which is in-
volved in trafﬁcking of myristolated proteins in Caenorhabditis (May et
al., 2014). It remains to be determined whether sequestration of
Unc119 to GA DPRs causes axonal transport defects in mammalian
neurons.
2.4. mRNP granules
TDP-43 itself is actively transported in motor neuron axons (Fallini
et al., 2012). It binds toG-quadruplex-containingmRNAs and assembles
into cytoplasmic mRNP granules that undergo bidirectional axonal
transport and facilitate delivery of mRNA for local translation
(Ishiguro et al., 2016; Alami et al., 2014). Pathogenic mutations in
TDP-43 (M337, A315T) caused reductions in net displacements in
both anterograde and retrograde directions of TDP-43 granules in
transfectedmouse cortical neurons and thiswas caused by reducedmo-
tility and increased reversal of direction. In contrast, in vivo examination
of Drosophila motor axons revealed that TDP-43M337V and TDP-
43A315T granules exhibited selectively impaired anterograde move-
ment (Alami et al., 2014). Similarly, in stem cell-derivedmotor neurons
from ALS patients bearing three different ALS-causing mutations in
TDP-43 (G298S, A315T, M337V), TDP-43-mediated anterograde trans-
port of NEFLmRNA was signiﬁcantly decreased approximately 10 days
after plating and this transport deﬁcit progressively worsened with
time in culture (Alami et al., 2014).
Together these data provide strong evidence for a potential involve-
ment of defective axonal transport in disease development and/or pro-
gression long before symptom onset. Indeed, axonal transport defects
are one of the earliest defects recorded in ALS, suggesting that they
may be a key pathogenic event in disease.
3. Molecular mechanisms of axonal transport defects in ALS
The underlying cause of axonal transport defects in ALS is not fully
understood. A small number of cases involve mutations in the axonal
transport machinery; these cases deﬁnitively link axonal transport de-
fects to disease. Several mechanisms by which axonal transport may
be perturbed in sporadic ALS and familial ALSwithmutations in non-ax-
onal transport genes have been proposed mostly based on studies of
mutant SOD1-related ALS. These include reductions in microtubule sta-
bility, mitochondrial damage, pathogenic signalling that alters phos-
phorylation of molecular motors to regulate their function or of
cargoes such as neuroﬁlaments to disrupt their associationwithmotors,
and protein aggregation (Table 1) (Fig. 1).
3.1. Mutations in axonal transport machinery genes as a primary cause of
disease
3.1.1. Dynein
Evidence that dysfunctional dynein/dynactin mediated axonal
transport is sufﬁcient to cause motor neuron degeneration ﬁrst came
to light when LaMonte et al. showed that disruption of dynein/dynactin
interaction by postnatal overexpression of p50/dynamitin, a 50-kDa
subunit of dynactin encoded by DCTN2, caused reduced axonal trans-
port in motor neurons and consequently led to a late-onset progressive
motor neuron disease phenotype in the transgenicmice (LaMonte et al.,
2002). This was followed by several studies showing that loss-of-func-
tion mutations in DCTN1, which encodes the p150Glued subunit of the
dynactin complex, cause a slowly progressive autosomal dominant dis-
tal hereditary motor neuropathy with vocal paresis (HMN7B) and ALS
(Puls et al., 2003; Puls et al., 2005; Munch et al., 2004; Munch et al.,
2005). The autosomal dominant G59S mutation that causes HMN7B is
in the cytoskeleton-associated protein glycine-rich (CAP-Gly) domain
of p150Glued (residues 48-90). This domain is involved in binding to
microtubules and end binding protein 1 (EB1). The G59S mutation has
been shown to reduce the binding afﬁnity of p150Glued for microtu-
bules, probably as a result of aberrant folding of the CAP-Gly domain
and aggregation of mutant p150Glued (Yan et al., 2015; Puls et al.,
2003; Levy et al., 2006). Interestingly these p150Glued G59S aggregates
associated withmitochondria (Levy et al., 2006). It is not clear what the
signiﬁcance of this association is but it may directly or indirectly affect
the axonal transport of mitochondria.
Homozygous p150Glued G59S knock-in embryos are not viable and
the heterozygous mice develop late-onset MND-like phenotypes in-
cluding abnormal gait, spinal motor neuron loss, increased reactive
astrogliosis, and accumulation of cytoskeletal and synaptic vesicle pro-
teins at neuromuscular junctions (Lai et al., 2007). A transgenic mouse
model of p150Glued G59S exhibited similar phenotypes (Laird et al.,
2008). Other disease causing autosomal dominant mutations in the
CAP-Gly domain of p150Glued involve substitution of phenylalanine
52, lysine 56, glycine 71, threonine 72 or glutamine 74. Similar to the
G59S mutation, the F52L and K56R mutations reduce the microtubule
binding afﬁnity of p150Glued but cause late-onset parkinsonism and
frontotemporal atrophy or progressive supranuclear palsy (PSP)
(Araki et al., 2014; Gustavsson et al., 2016) while residues 71, 72, and
74 which are within or close to the GKNDG microtubule binding motif
of the CAP-Gly domain (residues 68–72) also reduce the binding afﬁnity
of p150Glued formicrotubules but cause Perry syndromewith neuronal
inclusions containing TDP-43 (Farrer et al., 2009). Other p150Glued var-
iants including T1249I,M571T, R785W, and R1101Khave been reported
as possible risk factors for ALS, but further research is required to estab-
lish their role in disease (Munch et al., 2004; Munch et al., 2005;
Vilariño-Güell et al., 2009). It is nonetheless clear that mutations in
the DCTN1 gene cause a group of neurological disorders with overlap-
ping clinical and/or neuronal cell pathologies.
Coinciding with the discovery that p150Glued G59S causes HMN7B
(Puls et al., 2003), Hafezparast et al. demonstrated that single point
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mutations in the Dync1h1 gene, which encodes DHC, cause autosomal
dominant motor function defects and motor neuron degeneration in
the Legs at odd angles (Loa) and Cramping 1 (Cra1) mouse strains
(Hafezparast et al., 2003). The Loa and Cra1 mutations lead to F580Y
and Y1055C amino acid substitutions in DHC, respectively. Heterozy-
gous Loa and Cra1 mice display a limb grasping/clenching phenotype
and a progressive movement deﬁcit characterised by a low-based rep-
tilian-like gait. The severity of this abnormal way of walking increases
as the animals age (Hafezparast et al., 2003). Heterozygous Loa mice
also show a severe loss of proprioceptive sensory neurons (Chen et al.,
2007; Ilieva et al., 2008). Homozygous Cra1 and Loamice are not viable
with Cra1 homozygosity being embryonic lethal and Loa/Loamice die
within a day after birth as a result of the loss of N90% of their spinal
cord motor neurons by E18. Cultured motor neurons isolated from Loa
embryos exhibit signiﬁcantly reduced retrograde axonal transport and
aberrant extracellular signal-regulated kinases (ERK) 1/2 and c-Fos ex-
pression (Garrett et al., 2014; Hafezparast et al., 2003).
The F580Y mutation in DHC increases its afﬁnity for DICs and DLICs
while reducing association of dynactin to dynein (Deng et al., 2010).
Thus, impaired transport of cargoes such as signalling endosomes
which attach to dynein via dynactin may be explained by reduced
dynactin-dynein interaction while reduced motor function is predicted
to disturb retrograde transport more generally (Ori-McKenney et al.,
2010). Interestingly, the human variantsM581L and I584L that cause a
childhood formofmotor neuron disease known as spinalmuscular atro-
phy, lower extremity-predominant 1 (SMALED1), are only 1 and 2
amino acids, respectively, from the F580Y substitution in the Loa
mouse strain (Scoto et al., 2015; reviewed in Schiavo et al. (2013)). It
is not clear why these and several other mutations within different do-
mains of DYNC1H1 do not appear to play amore conspicuous role in the
pathogenesis of ALS. One explanation could be that thesemutations are
pathologically detrimental to mainly long motor neurons and therefore
spare other motor neuronal pools, degeneration of which tips the bal-
ance toward development of ALS.
Finally, dysregulation of transcription in a mouse model of theMND
spinal and bulbar muscular atrophy (SBMA) harbouring a pathogenic
expanded trinucleotide CAG repeat in the androgen receptor (AR) pro-
tein leads to reduced levels of p150GluedmRNA, which is accompanied
by impaired retrograde axonal transport (Katsuno et al., 2006). More-
over, loss of TDP-43 led to decreased expression of p150Glued and im-
paired autophagosome-lysosome fusion, which could be rescued by
transfecting the cells with p150Glued (Xia et al., 2015a, 2015b). Thus,
in some cases dynein function appears to be directly affected by dis-
ease-associated downregulation of p150Glued expression.
3.1.2. Kinesin
As is the case for dynein, disruption of kinesin can cause neurode-
generation. Conditional knockout of Kif5a in mice caused paralysis and
neurodegeneration concomitantwith a reduction in neuroﬁlament axo-
nal transport (Xia et al., 2003). Similarly, disruption of Kif1a in mice led
to severe motor and sensory defects and lethality within one day of
birth. Kif1a knockout reduces transport of synaptic vesicle precursors
and as a consequence causes decreases in synaptic vesicle density ac-
companied by neuronal degeneration in vivo and in cultured neurons
(Yonekawa et al., 1998).
Mutations in kinesin-1 or KIF1Ahave not directly been linked to ALS,
but mutations in KIF5A and KIF1A have been identiﬁed in hereditary
spastic paraplegia (HSP) forms of MND (Fichera et al., 2004; López et
al., 2015; Muglia et al., 2014; Citterio et al., 2015; Erlich et al., 2011;
Lee et al., 2015a). Both KIF5A and KIF1A mutations are located in the
motor or neck domains and appear to be loss-of-function variants
(Ebbing et al., 2008; Citterio et al., 2015; Erlich et al., 2011; Lee et al.,
2015a).
3.1.3. α-Tubulin
Microtubules play a pivotal role in the development and mainte-
nance of neuronal cell structures and functions and they are the essen-
tial tracks for both fast and slow long-distance axonal transport. As such,
it is not surprising that perturbations in the integrity of themicrotubule
cytoskeleton have been linkedwith several neurodegenerative diseases
includingMNDand this is exempliﬁed by thedisease-causingmutations
in α-tubulin and associated proteins (reviewed in El-Kadi et al., 2007;
Clark et al., 2016).
Several variants of the α-tubulin gene TUBA4A that destabilise the
microtubule network and diminish its re-polymerisation capability
have been identiﬁed as a possible cause of ALS (Smith et al., 2014).
Whether these mutations affect axonal transport has not yet been de-
termined, but since axonal transport prefers stable microtubules (Cai
et al., 2009; Reed et al., 2006) it is likely that theywill have a detrimental
effect. In this context, it is noteworthy that a missense mutation in the
tubulin-speciﬁc chaperone E (Tbce) gene that causes motor neuron de-
generation in the progressive motor neuronopathy (pmn)mouse strain,
amodel of humanMND, causesmicrotubule loss similar to that induced
by human ALS-linked TUBA4Amutations, and axonal transport defects
Table 1
Potential impact of MND-associated genes on the axonal transport pathway. Pathogenic variants of the proteins in this table have been linked to disrupted axonal transport.
(Ref: http://alsod.iop.kcl.ac.uk/home.aspx; Abel et al., 2012; this review.)
Gene Protein Potential consequence of mutation on axonal transport Disease
ALS2 Alsin Impaired endocytic trafﬁcking, signalling endosomes FALS (ALS2)
C9orf72 C9orf72 Defective transport of mitochondria FALS (ALS-FTD1); SALS; FTD
CHMP2B Charged multivesicular body protein
2B
Impaired endocytic trafﬁcking, signalling endosomes FALS (ALS17); SALS; FTD
DCTN1 Dynactin 1 (p150, glued homolog,
Drosophila)
Altered axonal transport and vesicle trafﬁcking, impaired signalling endosome trafﬁcking FALS; SALS; HMN7B; PMA; PSP;
Perry syndrome
FUS RNA-binding protein FUS Defective transport of mitochondria, aberrant microtubule acetylation FALS (ALS6); SALS
SPG11 Spatacsin Axonal destabilisation, reduced tubulin acetylation, reduced anterograde vesicle
transport
FALS (ALS5); HSP (SPG11)
SOD1 Superoxide dismutase 1 Impaired transport of mitochondria, microtubule stability, modulation of motor proteins
via p38 MAP kinase
FALS (ALS1); SALS
TARDBP TAR DNA-binding protein 43 Defective transport of mitochondria and mRNP granules; reduced expression of dynactin
1; aberrant microtubule stability/acetylation,
FALS (ALS10); SALS
TUBA4A Tubulin, alpha 4a Destabilisation of microtubules, general transport defect? FALS
VAPB Vesicle-associated membrane
protein-associated protein B
Impaired transport of mitochondria and vesicles FALS (ALS8); SMA; PMA
KIF1A Kinesin Family Member 1A Reduced kinesin-3 mediated transport HSP (SPG30)
KIF5A Kinesin heavy chain Reduced kinesin-1 mediated transport, impaired neuroﬁlament transport HSP (SPG10)
SPAST Spastin Destabilisation of microtubules, impaired transport of mitochondria and vesicles HSP (SPG4)
AR Androgen receptor Defective retrograde and anterograde transport, modulation of motor proteins via JNK SBMA
Abbreviations: FALS, familial ALS; SALS, sporadic ALS; SMA, spinalmuscular atrophy; SBMA, spinal and bulbarmuscular atrophy; PMA, progressivemuscular atrophy; FTD, frontotemporal
dementia.
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(Bommel et al., 2002; Martin et al., 2002; Schäfer et al., 2016). Finally,
mutations in spastin, a microtubule severing protein, which are the
most common cause of HSP (Hazan et al., 1999) impair microtubule dy-
namics (Wood et al., 2006; Trotta et al., 2004; McDermott et al., 2003;
Evans et al., 2005; Errico et al., 2002) and axonal transport of mitochon-
dria and APP vesicles (Kasher et al., 2009; Tarrade et al., 2006).
3.2. Pathogenic signalling as a cause of axonal transport defects
Although mutations in themolecular machinery of axonal transport
unequivocally link transport defects to neurodegeneration and disease,
these mutations are very rare. Nevertheless, as summarised above, axo-
nal transport defects are a common occurrence across severalmodels of
familial ALS and have been described in sporadic ALS. In this section we
summarise the possible mechanisms underlying axonal transport de-
fects in these cases.
3.2.1. Microtubule stability
Microtubules are dynamic structures that may undergo assembly
or disassembly by amechanism called dynamic instability (reviewed
in Matamoros and Baas, 2016). Some microtubules are more stable
than others resulting in two populations referred to as labile and sta-
ble microtubules. The stability of microtubules is mainly regulated
by microtubule associated proteins (MAPs) that bind along the
length of the microtubule, or by capture of the plus ends by for in-
stance protein complexes in the cell cortex. Several MAPs have
been shown to stabilise microtubules in neurons, including tau,
MAP2 and MAP1B. Tau, which is mainly expressed in neurons
where it localises to axons, is of particular interest in the context of
neurodegeneration and axonal transport. Mutations in tau have
been shown to cause frontotemporal dementia with parkinsonism
linked to tau mutations on chromosome 17 (FTDP-17T) and neuroﬁ-
brillary tangles whichmainly consist of hyperphosphorylated tau are
a pathological hallmark of Alzheimer's disease (Grundke-Iqbal et al.,
1986; reviewed in Iqbal et al., 2016). Tau has been shown to regulate
the axonal transport of several cargoes, includingmitochondria, pos-
sibly by regulating motor/microtubule interactions and/or by
stabilising microtubules (Ebneth, 1998; Stamer et al., 2002; Seitz,
2002; Trinczek et al., 1999). In a further link between neurodegener-
ation and defective axonal transport FTD-mutant tau inhibits axonal
transport (Zhang et al., 2004; Rodríguez-Martín et al., 2016; Gilley et
al., 2012). In addition, the PSP-associated R5L and R5H mutants in
the N-terminal projection domain of tau disrupt its interaction
with the C-terminus of p150Glued (Magnani et al., 2007). MAP1B
has been implicated in the retrograde transport of mitochondria
(Jimenez-Mateos et al., 2006) and disruption of FUTSCH/MAP1B in
Drosophila caused mitochondrial transport defects and progressive
neurodegeneration (Bettencourt da Cruz et al., 2005). Interestingly,
MAP1B mRNA is a translational target of TDP-43 and restoring its ex-
pression is protective in a Drosophila model of TDP-43-related ALS
(Coyne et al., 2014; Godena et al., 2011).
In addition to the labile and stable microtubule populations, a popu-
lation of ultra-stable, virtually non-dynamic, so-called cold-stable mi-
crotubules have been identiﬁed. Cold-stable microtubules are enriched
in axons and are made up by tubulin that has been post-translationally
polyaminated (Song et al., 2013a). Additional tubulinmodiﬁcations that
have been linked to microtubule stability are α-tubulin acetylation and
detyrosination, but it appears that these modiﬁcations accumulate on
longer-lived more stable microtubules rather than stabilise microtu-
bules per se. Hence the presence of acetylated or detyrosinatedα-tubu-
lin is a marker for stable microtubules. Post-translational tubulin
modiﬁcations have been linked to regulation of kinesin-1 mediated ax-
onal transport. Thus, kinesin-1 appears to preferentially bind to acety-
lated and/or detyrosinated microtubules. Microtubule acetylation has
been shown to stimulate kinesin-1-mediated transport (Hammond et
al., 2010; Reed et al., 2006), while tubulin detyrosination appears to
direct kinesin-1 to the axon (Konishi and Setou, 2009). If and how
post-translational modiﬁcations of tubulin affect dynein-mediated
transport is less clear, but increasing α-tubulin acetylation has been
shown to cause recruitment of dynein to microtubules (Dompierre et
al., 2007) and in case of axonemal dynein, microtubule acetylation in-
creasedmotility (Alper et al., 2014). Microtubule acetylation occurs pri-
marily on the epsilon amino group of the lysine at position 40 (K40) of
α-tubulin by α-tubulin acetyl transferase 1 (αTAT1, also known as
MEC17) (Shida et al., 2010; Akella et al., 2010), and deacetylation is me-
diated by histone deacetylase 6 (HDAC6) (Hubbert et al., 2002) and
Sirtuin-2 (SIRT2) (North et al., 2003). Interestingly loss of TDP-43 or
FUS has been shown to reduce HDAC6 expression (Kim et al., 2010),
suggesting that ALS-associated TDP-43 and FUS dysfunction may affect
axonal transport via changes to microtubule acetylation.
Measurement of in vivo microtubule polymerisation/
depolymerisation rates using mass spectrometry analysis of 2H2O-la-
belled tubulin revealed an increase in microtubule dynamics in pre-
symptomatic SOD1G93A transgenic mice, which correlated with
impaired slow axonal transport and progressively increased with dis-
ease. In addition, hyperdynamic microtubule subpopulations were
found in the lumbar segment of the spinal cord (where motor neuron
pathology occurs) and cerebral cortex, and in the peripheral motor
and sciatic mixed nerves, but not in sensory nerves (Fanara et al.,
2007). Direct identiﬁcation of dynamic microtubules by live imaging
of EB3-YFP also identiﬁed increased microtubule dynamics in intercos-
tal axons of Thy1:EB3-YFP–SOD1G93A and G85R transgenic mice
(Kleele et al., 2014).
Mutant SOD1A4V, G85R and G93A but not wild type SOD1 have
been shown to interact with tubulin and to affect microtubule stability
in vitro (Kabuta et al., 2009), providing a possible explanation for de-
creased microtubule stability in vivo. Alternatively, mutant SOD1-asso-
ciated reductions in microtubule stability may involve excitotoxicity-
related increases in intracellular calcium levels (reviewed in
Grosskreutz et al., 2010) that induce depolymerisation of microtubules
(Furukawa and Mattson, 1995), or oxidative stress (reviewed in Bozzo
et al., 2016),which has been shown to affectmicrotubule stability, albeit
in non-neuronal cells (Kratzer et al., 2012; Drum et al., 2016). Further
insults may involve changes to MAPs. MAP2, MAP1A, and tau levels
are reported to be reduced in the spinal cord of pre-symptomatic
SOD1G37R transgenic mice (Farah et al., 2003), and tau
hyperphosphorylation, which is predicted to reduce tau binding to mi-
crotubules and hence lower microtubule stability (Wagner et al.,
1996) was reported in the same mouse model (Nguyen et al., 2001).
Indications thatmicrotubule stabilitymay also be affected in sporad-
ic ALS come from the observation that in post-mortem spinal cord and
brain tissue sections of sporadic ALS cases hyperphosphorylated NF-H
positive spheroids also show positive staining for microtubule associat-
ed protein 6 (MAP6) (Letournel et al., 2003).MAP6,which is also known
as stable tubule only polypeptide (STOP), protects microtubules from
cold-induced depolymerisation (Delphin et al., 2012) and is preferen-
tially associated with stable microtubules in neurons (Slaughter and
Black, 2003). Its abnormal accumulation in the spheroids suggest dis-
ruption of stable microtubules and consequently disrupted transport,
which may be a contributory factor in sporadic ALS. Interestingly
MAP6 also interacts with TMEM106B, a major risk factor of
frontotemporal dementia (FTD) and a modiﬁer of C9orf72-associated
ALS and FTD that is involved in axonal transport of lysosomes
(Schwenk et al., 2014; van Blitterswijk et al., 2014; Gallagher et al.,
2014; Van Deerlin et al., 2010). Finally, a reduction in the levels of acet-
ylated tubulin has been linked to axonal instability and axonal transport
defects in familial ALS (ALS5) and HSP (SPG11) caused by mutations is
spatacsin (Perez-Branguli et al., 2014).
3.2.2. Mitochondrial damage
Mitochondria play a pivotal role in many cellular events including
energy metabolism and calcium handling. The latter is of special
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importance for motor neurons that rely greatly onmitochondria for cal-
cium buffering (reviewed in Grosskreutz et al., 2010). Furthermore, cal-
cium handling and ATP production by mitochondria are intimately
linked because mitochondrial calcium activates the rate-limiting en-
zymes of the Krebs cycle and thereby increases oxidative phosphoryla-
tion and ATP synthesis to match local energy demand. Evidence
suggests that both reduced mitochondrial energy metabolism and dys-
functional calciumhandling are likely to bemain contributors to the ax-
onal transport defects observed in ALS. Moreover, it is likely that
impaired transport ofmitochondria themselves and concomitant deple-
tion of mitochondria from axons (De Vos et al., 2007; Vande Velde et al.,
2011; Magrané et al., 2012; Wang et al., 2013) further exacerbates any
defects.
Damage to mitochondria is a well-documented, early phenomenon
in ALS (reviewed in Carrì et al., 2016; Grosskreutz et al., 2010; Tan et
al., 2014). In SOD1 or TDP-43-associated familial ALS mitochondrial
damage appears to be directly linked to pathological accumulations of
aggregated ALS mutant SOD1 or TDP-43 in mitochondria (Magrané et
al., 2009; Igoudjil et al., 2011; Pickles et al., 2013; Pickles et al., 2016;
Israelson et al., 2010; Li et al., 2010; Pasinelli et al., 2004; Liu et al.,
2004; Cozzolino et al., 2009; Wang et al., 2016). Whether aggregated
TDP-43 also accumulates in mitochondria in sporadic ALS is not yet
clear. ALSmutant SOD1 has been shown to speciﬁcally interact with spi-
nal cord mitochondria via direct interaction with voltage-dependent
anion channel 1 (VDAC1) and this accumulation is sufﬁcient and neces-
sary to damage mitochondria (Israelson et al., 2010). Accumulation of
ALSmutant TDP-43 inmitochondria appears to bemediated by internal
mitochondrial targeting sequences in TDP-43 (Wang et al., 2016). Mu-
tant SOD1 and TDP-43-mediated damage to mitochondria is believed
to severely impair the mitochondrial electron transfer chain and ATP
synthesis (Mattiazzi et al., 2002; Wang et al., 2016). Overexpression of
FUS has been shown to reduce mitochondrial ATP production, but
whether ALS mutant FUS accumulates in mitochondria is not clear
(Stoica et al., 2016). Mutations in the mitochondrial protein CHCHD10
have been shown to cause familial ALS (Bannwarth et al., 2014).
CHCHD10 is localised to contact sites between the inner and outermito-
chondrial membrane and mutations disrupt mitochondrial cristae and
impair mitochondrial genome maintenance (Genin et al., 2016). It is
not clear if CHCHD10 mutants directly affect mitochondrial function,
but since assembly and maintenance of the mitochondrial electron
transport chain relies on intact cristae (Vogel et al., 2006) and mito-
chondrial encoded subunits, it is likely that they do. Indeed, disruption
of cristae by mitoﬁlin depletion disrupts mitochondrial function (John
et al., 2005) and reduces mitochondrial membrane potential and ATP
levels (Ding et al., 2015). In agreement, respiratory chain complex I, III
and IV deﬁciency was identiﬁed in ﬁbroblasts of a CHCHD10 patient
(Bannwarth et al., 2014).
In addition to decreased ATP production, damage to mitochondria
has been associated with the disrupted calcium homeostasis observed
in in vitro and in vivo models of mutant SOD1, VAPB, TDP-43, and
FUS-related ALS (Carrì et al., 1997; Siklós et al., 1998; Morotz et al.,
2012; Stoica et al., 2014; Stoica et al., 2016). Compelling evidence sug-
gests that disrupted calcium homeostasis is caused by dysfunctional
communication between the endoplasmic reticulum (ER) and mito-
chondria at mitochondria-associated ER membranes (MAM). Reduced
ER/mitochondria contact sites have been observed in mutant SOD1,
SIGMAR1, TDP-43, and FUS-related ALS (Stoica et al., 2014; Stoica et
al., 2016;Watanabe et al., 2016; Lautenschlager et al., 2013). In contrast
overexpression of ALS mutant VAPBP56S increased ER/mitochondria
contacts (De Vos et al., 2012), but since in ALS8 patient-derived iPSC
neurons VAPB expression is down-regulated because of reduced ex-
pression of the VAPBP56S mutant (Mitne-Neto et al., 2011), it is likely
that in VAPBP65S-related ALS ER/mitochondria contacts are actually de-
creased as well. ER interacts with mitochondria via tethering proteins
(reviewed in Paillusson et al., 2016), such as the ER protein VAPB that
binds to the mitochondrial outer membrane protein PTPIP51 (De Vos
et al., 2012). In case of mutant TDP-43 and FUS the reduction in ER/mi-
tochondria contactwas the direct result of decreased binding of VAPB to
PTPIP51 (Stoica et al., 2014; Stoica et al., 2016). If this is also the case in
mutant SOD1 and SIGMAR1-related ALS remains to be determined. In-
terestingly, the levels of VAPB are reduced in the spinal cord of sporadic
ALS cases (Anagnostou et al., 2010), suggesting that disrupted ER-mito-
chondria communication could be a general feature in ALS and that re-
storing ER/mitochondria contact may be of therapeutic beneﬁt. In
agreement with this, neuronal overexpression of wild-type human
VAPB has been shown to slow disease and increase survival in
SOD1G93A transgenic mice (Kim et al., 2016).
The outer mitochondrial membrane protein Miro1 has emerged as
themain regulator of axonal transport of mitochondria although the re-
maining transport ofmitochondria inMiro1 knockout neurons suggests
that at least some mitochondrial transport is Miro1 independent
(Stowers et al., 2002; Glater et al., 2006; Russo et al., 2009; Babic et al.,
2015; López-Doménech et al., 2016). PossiblyMiro2 can partly compen-
sate for the loss of Miro1. Kinesin-1 connects to mitochondria through
interaction with Miro1 via the adaptor proteins TRAK1 and 2 (Glater
et al., 2006; Brickley et al., 2005; MacAskill et al., 2009a; Brickley and
Stephenson, 2011), and dynein has been shown to interact with both
Miro1 (Morlino et al., 2014) and TRAK1/2 (van Spronsen et al., 2013).
The Miro1/TRAK1 complex further associates with disrupted in schizo-
phrenia 1 (DISC1) and this has been linked to regulation of anterograde
mitochondrial transport (Atkin et al., 2011; Ogawa et al., 2014; Norkett
et al., 2016), possibly via interaction with the anchoring protein
syntaphilin (Park et al., 2016) or NDE1 and glycogen synthase kinase
3β (GSK3β) (Ogawa et al., 2016) or by regulating mitochondrial bioen-
ergetics via interactionwithmitoﬁlin and themitochondrial contact site
and cristae organising system (MICOS) complex (Park et al., 2010;
Piñero-Martos et al., 2016).
Miro1 is an atypical Rho GTPase comprised of two GTPase domains
separated by two calcium-binding E-helix-loop-F-helix (EF)-hand mo-
tifs, and is anchored in themitochondrial outermembrane by a C-termi-
nal transmembrane domain (Fransson et al., 2006). Miro1 plays a
central role in the regulation of mitochondrial axonal transport in re-
sponse to calcium and mitochondrial damage (Russo et al., 2009;
Babic et al., 2015; Saotome et al., 2008; Weihofen et al., 2009; Wang et
al., 2011).
Binding of calcium to the Miro EF-hand motifs halts anterograde
transport of mitochondria by regulating the interaction of kinesin-1
with Miro1 such that either kinesin-1 binding to microtubules or to
Miro1 is disrupted and this appears an important mechanism to regu-
late mitochondrial transport in response to physiological stimuli
(Macaskill et al., 2009b; Wang and Schwarz, 2009; Stephen et al.,
2015). Increased cytosolic calcium levels have been reported in cellular
models and in motor neurons from transgenic ALS models (Morotz et
al., 2012; Siklós et al., 1998) and have been shown to disrupt transport
of mitochondria via Miro1 in VAPBP56S-expressing neurons (Morotz
et al., 2012).
Inmitophagy, loss ofmitochondrialmembrane potential or accumu-
lation of misfolded proteins in mitochondria, leads to the stabilisation
and activation of the Ser/Thr kinase PINK1 on the outer mitochondrial
membrane. PINK1 subsequently phosphorylates ubiquitin on Ser65
which drives recruitment of the cytosolic E3 ubiquitin ligase Parkin to
damaged mitochondria. PINK1 further phosphorylates Parkin leading
to its full activation. PINK1 also forms a complex with Miro1 and TRAK
and phosphorylates Miro1 in response to mitochondrial damage
(Weihofen et al., 2009; Wang et al., 2011; Shlevkov et al., 2016). Phos-
phorylatedMiro is targeted for proteasomal degradation in a Parkin-de-
pendent manner and as a result kinesin-1 detaches from the
mitochondrial surface and mitochondrial movement is arrested
(Wang et al., 2011). In addition, Parkin ubiquitinates other outer mito-
chondrial membrane substrates, such as mitofusin, to isolate the dam-
aged mitochondria and to recruit autophagy receptors such as NDP52,
optineurin (both substrates of TANK-binding kinase (TBK1)) and p62
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to deliver the damaged mitochondria to autophagosomes. Interestingly
loss-of-function mutations in optineurin, p62 and TBK1 have been
shown to cause ALS, and the C9orf72 protein regulates autophagy and
interacts with SMCR8 which is itself a TBK1 substrate (Webster et al.,
2016a; Webster et al., 2016b; Ugolino et al., 2016; Yang et al., 2016).
In agreement with ALS-associated mitochondrial damage leading to
PINK1/Parkin-mediated halting of mitochondrial transport, decreased
levels of Miro1 have been reported in SOD1G93A and TDP-43M337V
transgenic mice as well as in the spinal cord of ALS patients (Zhang et
al., 2015) while down-regulation of either PINK1 or Parkin partially res-
cued the locomotive defects and enhanced the survival rate in transgen-
ic ﬂies expressing FUS (Chen et al., 2016). Interestingly mitochondria
remained homogeneously distributed throughout the axons of Miro1
knockout neurons despite a 65% decrease in trafﬁcking (López-
Doménech et al., 2016). This is reminiscent of the situation in
SOD1G93A expressing neurons where reduced anterograde transport
and the resulting loss of axonal mitochondria did not translate into
changes in the overall distribution of mitochondria in the axon, but
rather caused a compensatory increase in inter-mitochondrial distance
(De Vos et al., 2007).
Whethermitochondrial axonal transport defects are part of all ALS is
not yet clear, but mitochondrial damage (Sasaki and Iwata, 2007; Allen
et al., 2015), dysfunctional calciummetabolism (Curti et al., 1996; Siklos
et al., 1996) and reduced expression of Miro1 (Zhang et al., 2015) have
been found in sporadic ALS cases. Furthermore, energy defects and re-
duced calcium buffering capacity caused by reduced numbers of mito-
chondria in the distal axon, exacerbated by mitochondrial and MAM
dysfunction, may explain the selective vulnerability of motor neurons
because they are particularly reliant on mitochondria for calcium buff-
ering as a consequence of their relative lack of cytosolic calcium binding
proteins (Grosskreutz et al., 2010). One obvious way in which mito-
chondrial damage and concomitant mitochondrial transport defects
and depletion of mitochondria from axons (De Vos et al., 2007; Vande
Velde et al., 2011; Magrané et al., 2012; Wang et al., 2013) could affect
the transport of other cargoes such as APP vesicles or signalling
endosomes is by starving molecular motors of ATP. However, since it
has been shown that neuronal BDNF, APP, and TrkB vesicles harbour
most glycolytic enzymes and “self-propel” using their own source of
glycolytic ATP independent of mitochondria (Hinckelmann et al.,
2016; Zala et al., 2013) reduced axonal mitochondrial ATP production
may not be sufﬁcient to halt axonal transport. Alternatively, mitochon-
drial damage and/or lack of axonal mitochondria may affect transport
by disturbance of calcium signalling. Indeed, MAP6’s microtubule
stabilisation activity is regulated by calcium/calmodulin. Increased cal-
cium is associated with increased MAP6/calmodulin interaction and re-
ducedmicrotubule binding (Job et al., 1981; Lefèvre et al., 2013). Hence
increases in cytosolic calcium caused by mitochondrial dysfunction
could destabilise microtubules and consequently impair axonal
transport.
3.2.3. Kinase signalling
Axonal transport is regulated by phosphorylation (reviewed in
Gibbs et al., 2015). Direct phosphorylation of molecular motors has
been shown to affect motor activity and phosphorylation of adapter
proteins and cargoes has been shown to affect attachment of motors
to cargo. Furthermore, phosphorylation ofMAPs has been shown to reg-
ulatemicrotubule stability and hence axonal transport. Several of the ki-
nases involved in the regulation of axonal transport have been
associated with ALS.
3.2.3.1. p38 MAP kinase. A number of groups have shown that p38mito-
gen-activated protein (MAP) kinase is overactivated in the spinal cord
of SOD1G93A transgenic mice and in familial and sporadic human ALS
cases (Morﬁni et al., 2013; Tortarolo et al., 2003; Ackerley et al., 2004;
Bendotti et al., 2004; Dewil et al., 2007). Although the precise role of
p38 MAP kinase in disease is not fully understood, inhibition of p38
MAP kinase protected mutant SOD1 expressing motor neurons in vitro
and in vivo in SOD1G93A transgenic mice, suggesting an active role in
the neuropathology of disease (Dewil et al., 2007). The activation of
p38 MAP kinase probably involves excitotoxic glutamate signalling
(Stevenson et al., 2009; Kawasaki et al., 1997; Jeon et al., 2000; Chen
et al., 2003) and protein stress by for example misfolded SOD1 (Bosco
et al., 2010).
p38MAP kinase has been shown to phosphorylate kinesin-1 on ser-
ines 175 and 176 and this inhibited translocation of kinesin-1 along ax-
onal microtubules (Morﬁni et al., 2013) while p38 MAP kinase
phosphorylation of KLC inhibited anterograde transport of mitochon-
dria (De Vos et al., 2000). p38MAP kinase also phosphorylates neuroﬁl-
ament medium polypeptide (NF-M)/NF-H sidearms (Ackerley et al.,
2004; Guidato et al., 1996) which slows their transport, probably by re-
ducing neuroﬁlament binding to molecular motors (Ackerley et al.,
2003; Jung et al., 2005). Supporting a role for p38MAP kinase in neuro-
ﬁlament pathology, increased co-localisation of p38 MAP kinase and
phosphorylated neuroﬁlaments was observed in degenerating neurons
at the onset of disease in SOD1G93A transgenic mice (Bendotti et al.,
2004). Interestingly, the anti-glutamatergic drug riluzole, currently the
only approved drug for the treatment of ALS, has been shown to prevent
p38 MAP kinase activation by excitotoxic glutamate and restore axonal
transport of neuroﬁlaments (Stevenson et al., 2009).
Using a monoclonal antibody to misfolded SOD1 (C4F6), Bosco et al.
(2010) revealed the presence of a misfolded wild-type SOD1 in post-
mortem human spinal cord tissues of 4 out of 9 sporadic ALS cases.
Misfolded wild-type SOD1 puriﬁed from sporadic ALS tissues inhibited
anterograde axonal transport in isolated squid axoplasm assays to the
same extend as a familial ALS-associated SOD1H46R mutant, and this
was found to involve the activation of p38 MAP kinase and subsequent
kinesin-1 phosphorylation (Bosco et al., 2010). A later study using YFP-
tagged SOD1G85R revealed that Hsc70 and its nucleotide exchange fac-
tor Hsp110 prevented SOD1G85R-induced activation of p38MAP kinase
and the transport defect exerted by mutant SOD1G85R, possibly by en-
hancing disaggregation of SOD1 (Song et al., 2013b). Interestingly, over-
expression ofHsp110has been shown tomarkedly increase the life span
of YFP-SOD1G85R and SOD1G93A transgenic mice (Nagy et al., 2016).
3.2.3.2. JNK. JNK/c-Jun signalling has been implicated in TDP-43 induced
protein toxicity (Suzuki and Matsuoka, 2013; Meyerowitz et al., 2011;
Lee et al., 2016; Zhan et al., 2015), and increased amounts of phosphor-
ylated c-Jun have been reported in SOD1G93A transgenicmice (Jaarsma
et al., 1996). The latter appears to correlate with an increase in retro-
grade JNK signalling rather than overall increased activation of JNK in
motor neurons (Perlson et al., 2009; Holasek et al., 2005). JNK has also
been shown to be activated by glutamate excitotoxicity (Chen et al.,
2003; Schwarzschild et al., 1997) but if this is the case in ALS is not
clear. Indeed, Dewil et al. (2007), did not ﬁnd JNK activation in motor
neurons and microglia from SOD1G93A transgenic mice (Dewil et al.,
2007).
JNK has been shown tomodulate both kinesin/microtubule (Morﬁni
et al., 2006; Stagi et al., 2006) and kinesin/cargo interactions (Horiuchi
et al., 2007). The former has been linked to JNK-mediated phosphoryla-
tion of the kinesin-1 motor domain (Morﬁni et al., 2006) whereas the
latter involves disruption of the binding of the cargo adapter JIP1 to
kinesin-1 (Horiuchi et al., 2007). JNK also interacts with dynein via
binding of JIP3 to p150Glued andDLIC and this is required for retrograde
transport of activated JNK (Drerup and Nechiporuk, 2013; Cavalli et al.,
2005; Huang et al., 2011). Whether activated JNK regulates its own ret-
rograde transport is not yet clear. Activated JNKmay also have a general
effect on axonal transport by regulation of Dishevelled-mediatedmicro-
tubule stability (Ciani and Salinas, 2007). Changes to theWNT signalling
pathway have been described in ALS but if these affect microtubules re-
mains to be determined (Chen et al., 2012b; Yu et al., 2013; Chen et al.,
2012a). As was the case for p38 MAP kinase, JNK activation has been
linked tomisfolded protein stress. Neuropathogenic forms of huntingtin
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and AR were shown to inhibit axonal transport (Szebenyi et al., 2003)
and subsequent studies showed that this inhibition is JNK mediated
(Morﬁni et al., 2009; Morﬁni et al., 2006). Finally, JNK also phosphory-
lates NF-M/NF-H sidearms (Ackerley et al., 2000).
Overactivation of GSK3β has been reported in the brain and spinal
cord of SOD1G93A transgenic mice and spinal cord samples from spo-
radic ALS patients (Hu et al., 2003a; Hu et al., 2003b; Yang et al., 2008;
Koh et al., 2005). Nevertheless, the involvement of GSK3β in ALS re-
mains controversial. Inhibition of GSK3β was protective in SOD1G93A
transgenic mice in some studies (Koh et al., 2007; Feng et al., 2008)
but not in others (Gill et al., 2009; Pizzasegola et al., 2009) Moreover,
lithium, a known inhibitor of GSK3β, did not show any evidence of ben-
eﬁt on survival in patients with ALS (UKMND-LiCALS et al., 2013).
3.2.3.3. GSK3β.GSK3β negatively regulates axonal transport in a number
of ways. GSK3β-mediated phosphorylation of KLC2 has been shown to
release kinesin-1 from vesicles in a regulatory pathway that involves
Cyclin-dependent kinase 5 (Cdk5) (see below), lemur tyrosine kinase
2 (LMTK2) and protein phosphatase 1 (PP1) (Manser et al., 2012;
Morﬁni et al., 2004; Morﬁni et al., 2002). Phosphorylation of DIC1B
and DIC2C by GSK3β inhibited retrograde transport of acidic organelles
by reducing the binding of NDEL1 to DICs (Gao et al., 2015). Further-
more, GSK-3β-dependent phosphorylation of the motor adapter
BICD1 is required for its binding to dynein (Fumoto et al., 2006). Since
NDEL1, LIS1 and BICD are involved in regulation of dynein function,
GSK3βmay be affecting multiple retrograde cargoes and this may ex-
plain the defects in retrograde transport reported in ALS. NDE1, LIS1
and GSK3β have also been shown to interact with TRAK1 and this inter-
action is involved in regulating axonal transport of mitochondria. Over-
expression of NDE1 increased retrograde transport of mitochondria,
while activation of GSK3β stimulated anterograde transport (Ogawa
et al., 2016). Consistent with NDE1/LIS1 regulation of mitochondrial
transport it was shown that reducing the levels of LIS1 increases mito-
chondrial trafﬁcking in adult Drosophila neurons (Vagnoni et al.,
2016). Interestingly mutations in LIS1, NDE1 and BICD2 have all been
associated with neurodegeneration (Lipka et al., 2013).
GSK3β is a major tau kinase involved in neurodegeneration
(reviewed in Hanger and Noble, 2011; Llorens-Martín et al., 2014).
Phosphorylation of tau by GSK3β releases tau from microtubules and
destabilises microtubules (Wagner et al., 1996) which can disrupt axo-
nal transport. ALS-associated defects in ER/mitochondria communica-
tion are linked to activation of GSK3β (Stoica et al., 2016; Stoica et al.,
2014). Thus, GSK3βmay also indirectly regulate axonal transport by af-
fecting ER/mitochondria communication as described above. GSK3β has
also been described as a neuroﬁlament kinase that affects anterograde
neuroﬁlament transport by regulating neuroﬁlament bundling (Lee et
al., 2014).
3.2.3.4. Cdk5. Cdk5 is a member of the cyclin-dependent kinase family
expressed in post-mitotic cells including neurons. Under normal cir-
cumstances Cdk5 is activated by p35, which in turn is phosphorylated
by Cdk5 leading to its degradation by the proteasome and subsequent
inactivation of Cdk5. Under stress conditions p35 is cleaved by calpain
to generate a p25 fragment which retains its Cdk5 activation activity,
but lacks the regulatory phosphorylation site, leading to sustained acti-
vation of Cdk5 and this has been linked to neurodegeneration (Patrick
et al., 1999; Kusakawa et al., 2000; Lee et al., 2000). Transgenic overex-
pression of p25 in neurons caused MND reminiscent of ALS (Bian et al.,
2002) and aberrant activation of Cdk5 has been reported in the spinal
cord of mouse models of ALS (Nguyen et al., 2001; Klinman and
Holzbaur, 2015; Rao et al., 2016). Consistent with a possible role of
p25 dependent overactivation of Cdk5 in ALS, overexpression of the en-
dogenous calpain inhibitor calpastatin delayed disease onset and in-
creased survival of SOD1G93A transgenic mice (Rao et al., 2016).
However, since genetic ablation of the Cdk5 activator p35 did not affect
the onset and progression of motor neuron disease in SOD1G93A
transgenic mice (Takahashi and Kulkarni, 2004), the protective effect
of calpastatin may actually derive from its inhibition of MAP2 and neu-
roﬁlament proteolysis. Cdk5 has been shown to phosphorylate
neuroﬁlaments and this regulates their transport (Shea et al., 2004a;
Shea et al., 2004b; Ackerley et al., 2003). Cdk5 also regulates antero-
grade trafﬁcking of vesicles by activating GSK3β (Manser et al., 2012;
Morﬁni et al., 2004; Morﬁni et al., 2002) and by phosphorylation of
NDEL1 Cdk5 inhibits dynein-mediated transport of lysosomes,
autophagosomes, mitochondria, and signalling endosomes (Klinman
and Holzbaur, 2015). Interestingly inactivation of Cdk5with roscovitine
rescued defective retrograde transport of TrkB vesicles in DRG neurons
cultured from 90- to 100-day-old SOD1G93A transgenic mice (Klinman
and Holzbaur, 2015).
3.2.4. Protein aggregation
Protein misfolding and aggregation is a hallmark pathology of ALS
(reviewed in Parakh and Atkin, 2016). TDP-43 aggregates are found in
almost all ALS cases, including sporadic cases and most familial ALS
cases. ALS patients with SOD1 mutations are a notable exception but
do however exhibit aggregated mutant SOD1 in affected neurons.
Other familial ALS associatedmutant proteins that are prone to aggrega-
tion are TDP-43 itself, FUS, and the DPRs generated by RAN translation
of the expanded G4C2 repeats in C9orf72. Furthermore, a number of fa-
milial ALS-associated proteins are known to be involved in protein qual-
ity control mechanisms, including C9orf72, valosin-containing protein
(VCP), sequestosome-1/p62, ubiquilin-2, optineurin, dynactin, and
TBK1 (reviewed in Webster et al., 2016b).
As discussed above, misfolded SOD1 disrupts anterograde transport
by activation of p38MAP kinase (Bosco et al., 2010). In addition, dynein
has been shown to interactwith ALS-mutant SOD1A4V, G85R, andG93A
but not wild type SOD1 via DIC (Zhang and Zhu, 2006). Moreover dy-
nein and ALSmutant SOD1 appeared tomostly colocalise in ALSmutant
SOD1 protein aggregates in cultured motor neurons (Ligon et al., 2005)
and in vivo in SOD1G93A and G85R transgenic mice (Zhang and Zhu,
2006) supporting the notion that reduced retrograde axonal transport
in SOD1-related ALS may at least in part be caused by sequestration of
dynein. It is not clear if any of the other misfolded proteins associated
with ALS disrupt transport in a similar fashion.
In addition to TDP-43 aggregates, accumulations of neuroﬁlaments
and peripherin in axonal spheroids and motor neuron cell bodies are a
pathological hallmark of ALS (reviewed in Gentil et al., 2015; Xiao et
al., 2006). As described above aberrant phosphorylation of
neuroﬁlaments appears to play a major role in the dysregulation of
their transport and in the formation of these pathological inclusions. It
has been suggested that accumulation of neuroﬁlamentsmay also affect
the transport of other cargoes. Indeed, changes in neuroﬁlament organi-
sation due to loss of neuroﬁlament light polypeptide (NF-L) in
peripherin overexpressing cells disrupted transport of mitochondria
(Perrot and Julien, 2009). Interestingly, peripherin upregulation in com-
bination with NF-L downregulation was also found in the spinal cord of
TDP-43G348C and A315T transgenic mice (Swarup et al., 2011). This
may be due to TDP-43 mediated regulation of neuroﬁlament and
peripherin mRNA processing (Strong et al., 2007; Swarup et al., 2011).
How neuroﬁlament accumulations disrupt transport is not entirely re-
solved butmay involve blockage of the axon or disruption of themicro-
tubule network. Indeed, neuroﬁlament depletion caused a stabilisation
of microtubules in pmnmutant motor neurons by reducing the seques-
tration of Stat3/stathmin to neuroﬁlaments (Yadav et al., 2016).
3.2.5. Non-cell autonomous toxicity
Although the selective degeneration ofmotor neurons deﬁnes ALS, it
is now clear that non-neuronal cells in the CNS such as astrocytes, mi-
croglia, and oligodendrocytes do contribute to disease. How these
non-neuronal CNS cells contribute to neurodegeneration is still under
debate, butmay involve reducedmetabolic support, release of cytokines
and toxins, and glutamate excitotoxicity (reviewed in Ferraiuolo, 2014).
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Activated microglia-conditioned medium has been shown to induce
neuritic beading in cultured motor neurons via N-methyl-D-aspartate
(NMDA) receptor signalling (Takeuchi et al., 2005). NMDA-signalling
mediated inhibition of mitochondrial complex IV and a subsequent de-
cline in ATP levels reduced fast axonal transport and led to abnormal ac-
cumulation of tubulin, neuroﬁlament, kinesin and dynein in the
spheroids prior to the death of themotor neurons. Thus, these data sug-
gest a link between the non-cell autonomous toxicity ALS and a down-
stream disruption of fast axonal transport. Similarly, expression of a
mutant AR transgene solely in skeletal muscle ﬁbres caused an andro-
gen-dependent motor neuron degeneration and a SBMA phenotype, in-
cluding defects in retrograde transport (Halievski et al., 2016).
4. Restoring transport as a treatment for ALS?
As discussed above, axonal transport defects are part of ALS neu-
ropathology. Axonal transport defects are one of the earliest insults
observed in ALS, arguing that they may be causative for disease. Ge-
netic evidence showing that mutations in molecular motors and mi-
crotubules are sufﬁcient to cause ALS and ALS-related motor neuron
disorders, conﬁrms that axonal transport defects can cause neurode-
generation. Thus, the question arises if restoring axonal transport
may be of therapeutic beneﬁt in ALS patients. The emerging insight
in the molecular mechanisms underlying axonal transport defects
in ALS reviewed above has allowed to devise strategies to restore
transport and to begin to answer this question (Table 2).
4.1. Restoration of mitochondrial transport
Defects in axonal transport of mitochondria are a robust ﬁnding in
ALS, and because they are observed as early as at embryonic stage in
ALSmousemodelsmitochondrial transport defects have been proposed
to play an important role in disease. However, increasing axonal motil-
ity of mitochondria in SOD1G93A transgenic mice by depletion of the
mitochondrial docking protein syntaphilin did not alter the course of
disease in SOD1G93A transgenic mice (Zhu and Sheng, 2011). It has to
be noted that Zhu et al., only veriﬁed increased axonal transport in
DRG neurons which are not a target of ALS (Zhu and Sheng, 2011), but
it is perhaps not surprising that restoring transport of damaged
mitochondria does not affect the disease process. Indeed, the robust re-
duction in anterograde transport of mitochondria following ALS-associ-
ated damage may be indicative of increased clearance of mitochondria
by mitophagy. Nevertheless, these ﬁndings suggest that impairment of
mitochondrial transport may not be a primary cause of motor neuron
degeneration and that any strategy to improve transport may need to
be combined with drugs targeting mitochondrial dysfunction.
4.2. Restoration of endosomal trafﬁcking
It is possible that disrupted transport of another cargo than mito-
chondria is essential for motor neuron survival. One such cargo may
be BDNF/TrkB signalling endosomes that are retrogradely transported
toward the soma (reviewed in Schmieg et al., 2014). Indeed, targeted
disruption of retrograde transport causes ALS-like disease in a number
of models (see above) and BDNF is known to support motor neurons
in vitro and in vivo (Yan et al., 1993; reviewed in Sendtner et al., 1996).
In line with this possibility the unexpected amelioration in disease
progression observed in SOD1G93A transgenic mice crossed with Loa
micewas accompanied by a full rescue of the axonal transport of signal-
ling endosomes (Kieran et al., 2005). Theprotective effect of the Loamu-
tation in dynein potentially relates to reductions in mitochondrial
damage and associated axonal transport defects in SOD1G93A–Loa/+
mice. Indeed, the amount of mitochondria-associated mutant SOD1
protein was markedly reduced in SOD1G93A–Loa/+ mice and this cor-
related with improvements in mitochondrial respiration and mem-
brane potential in SOD1G93A–Loa/+ motor neurons (El-Kadi et al.,
2010). Mutant SOD1 has been shown to interact with dynein and this
interaction was critical for the formation of SOD1 aggregates (Strom et
al., 2008; Zhang et al., 2007). Hence a possible explanation for the resto-
ration of endosome trafﬁcking in SOD1G93A–Loa/+ mice is that re-
duced interaction of mutant SOD1 with Loa dynein restores transport
of retrograde cargoes and that concomitant reductions in mutant
SOD1 aggregates that are damaging to mitochondria restore mitochon-
drial function and possibly transport.
Overexpression of BICD2-N, which chronically impairs dynein/
dynactin function, also delayed disease onset and increased life span
of ‘low-copy’ SOD1G93A transgenic mice by 14% (Teuling et al., 2008).
Possibly, in this case reduced transport of signalling endosomes may
dampen the effects of a switch in retrograde signalling from survival
to stress in SOD1G93A–Loa/+ transgenic mice (Perlson et al., 2009).
4.3. Targeting microtubules to restore transport
Microtubules are emerging as an attractive target tomodulate ax-
onal transport with several laboratories reporting beneﬁcial effects
of microtubule-binding drugs that were originally developed as anti-
mitotic agents for the treatment of cancer (reviewed in Stanton et al.,
2011). Treatment of SOD1G93A transgenic mice with noscapine,
which attenuates microtubule dynamics, partially stabilised micro-
tubules and delayed onset of disease compared to the untreated
SOD1G93A transgenic mice and this effect increased when adminis-
tered in combination with the anti-inﬂammatory PPARgamma ago-
nist pioglitazone. Interestingly pioglitazone treatment per se also
stabilised hyperdynamic microtubules (Fanara et al., 2007). Similar-
ly, low doses of noscapine rescued peroxisome trafﬁcking defects in
Table 2
Restoring transport as a treatment for ALS. Summary of in vivo studies using the SOD1G93A transgenic mouse model, see text for details.
Target Treatment Effect on transport Effect on disease Reference
Mitochondrial docking Syntaphilin knockout Increases mitochondrial trafﬁcking in DRGs No effect Zhu and Sheng (2011)
Dynein/retrograde transport Cross with Loa Restores retrograde endosome trafﬁcking Prolonged survival Kieran et al. (2005)
Dynein/retrograde transport Cross with Cra1 Not determined Prolonged survival Teuchert et al. (2006)
Dynein/retrograde transport BICD2-N knockout Not determined Prolonged survival Teuling et al. (2008)
Microtubules noscapine Normalises slow axonal transport defects Prolonged survival Fanara et al. (2007)
HDAC6 HDAC6 knockout Not determined Prolonged survival Taes et al. (2013)
p38 MAPK kinase Semapimod Not determined Prolonged survival Dewil et al. (2007)
Calpain/Cdk5 Calpastatin overexpression Not determined Prolonged survival Rao et al. (2016)
Cdk5 p35 KO Not determined No effect Takahashi and Kulkarni (2004)
GSK3β GSK-3 inhibitor VIII Not determined Prolonged survival Koh et al. (2007)
GSK3β Lithium + valproate Not determined Prolonged survival Feng et al. (2008)
GSK3β Lithium Not determined No effect Gill et al. (2009)
GSK3β Lithium Not determined No effect Pizzasegola et al. (2009)
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HSP patient-derived olfactory neurosphere-derived cells and this
correlated with a restoration of acetylated microtubules in these
cells (Fan et al., 2014). In the same study, taxol, vinblastine and
epothilone were reported to have a beneﬁcial effect similar to that
of noscapine (Fan et al., 2014). While both taxol and epothilone are
known to stabilise microtubules, vinblastine is a microtubule-
destabilising agent. However, it is likely that at the low doses used
vinblastine attenuates microtubule dynamics rather than causes
depolymerisation (Panda et al., 1996). If these drugs have a beneﬁ-
cial effect on axonal transport, axonal swellings and gait abnormali-
ties in HSP models such as Spast∆E7/∆E7 (Kasher et al., 2009) or Sp∆/∆
(Tarrade et al., 2006) mice remains to be determined, but epothilone
also has shown beneﬁcial effects in models of Alzheimer's disease
(Brunden et al., 2010; Barten et al., 2012) and Parkinson's disease
(Cartelli et al., 2013) and was in a clinical phase I trial for Alzheimer's
disease (ClinicalTrials.gov NCT01492374).
Following a report that microtubule acetylation increased kinesin-1
mediated transport (Reed et al., 2006) several laboratories have ex-
plored the beneﬁcial effects of acetylation enhancing drugs on axonal
transport and neurodegeneration. Most of these studies have focussed
on inhibition of the tubulin deacetylases HDAC6 (Hubbert et al., 2002)
and SIRT2 (North et al., 2003), although the role of SIRT2 in mouse
CNS remains questionable (Bobrowska et al., 2012; Taes et al., 2013).
For example, HDAC6 inhibition compensated for axonal transport de-
fects in Huntington's disease (Dompierre et al., 2007), reversed axonal
loss in vivo in mutant HSPB1-induced Charcot-Marie-Tooth disease
(d'Ydewalle et al., 2011), and restored axonal transport and locomotor
defects in a Drosophilamodel of mutant LRRK2-associated Parkinson's
disease (Godena et al., 2014) while loss of HDAC6 rendered neurons re-
sistant to amyloid-β-mediated impairment of mitochondrial trafﬁcking
and rescuedmemory function in APPPS1-21 transgenic Alzheimer's dis-
ease mice (Govindarajan et al., 2013). Genetic ablation of HDAC6 in
SOD1G93A transgenic mice signiﬁcantly extended the survival without
affecting the timing of disease onset (Taes et al., 2013). Deletion of
HDAC6 increased levels of acetylated tubulin, but it is not clear if this re-
stored the axonal transport defects reported in this mouse model (Taes
et al., 2013). Although microtubule acetylation appears to be an attrac-
tive target, a possible caveat of long-term HDAC6 inhibition is that
HDAC6 also plays a critical role in the clearance of aggregated proteins
by autophagy (aggrephagy) (Kawaguchi et al., 2003) and has been im-
plicated in clearance of mutant SOD1 (Lee et al., 2015b; Xia et al.,
2015a, 2015b; Gal et al., 2013).
4.4. Targeting kinases to restore transport
A number of studies have targeted kinases involved in the regulation
of axonal transport. Inhibition of p38 MAPK kinase protected motor
neurons but only modestly prolonged survival in SOD1G93A transgenic
mice (Dewil et al., 2007). Similarly, inhibition of Cdk5 by overexpression
of calpastatin delayed disease onset and increased survival of
SOD1G93A transgenic mice (Rao et al., 2016). Inhibition of GSK3β was
found to be protective in SOD1G93A transgenic mice (Koh et al., 2007;
Feng et al., 2008). Although these studies reported beneﬁts, none
analysed axonal transport so it remains to be seen if restoration of axo-
nal transport exerts the beneﬁcial effects observed. Moreover, since ge-
netic ablation of the Cdk5 activator p35 did not affect the onset and
progression of motor neuron disease in SOD1G93A transgenic mice
(Takahashi and Kulkarni, 2004), and some studies found no effects of
GSK3β inhibition (Gill et al., 2009; Pizzasegola et al., 2009) it is clear
that further conﬁrmation is required.
5. Conclusions
The link between axonal transport defects and ALS and other neuro-
degenerative diseases is very strong and over the past two decades our
understanding of axonal transport defects has increased considerably.
Nevertheless, there are still large gaps in our knowledge with regards
to this link. For example, how do mutations in the same motors cause
different neurodegenerative diseases, or why do they speciﬁcally target
neurons, and often one type of neurons but not others in the same per-
son? One explanation is the unique geometry and/or physiology of neu-
rons renders them selectively vulnerable to insults to the transport
system. As discussed above, in case of motor neurons, increased suscep-
tibility may derive from their particular reliance on mitochondria for
calcium buffering. In this scenario, mitochondrial damage combined
with reduced numbers of axonal mitochondria due to defective axonal
transport disrupts calcium homeostasis which in turn leads to reduced
microtubule stability, impaired binding of motor proteins to the micro-
tubules, and defective axonal transport which then exacerbates calcium
dysfunction in a vicious circle. An alternative explanation may be dis-
ruption to motor neuron speciﬁc retrograde signalling pathways. How-
ever, while in ALSmotor neurons exhibit the earliest signs of pathology
and the highest vulnerability, there is clear evidence of pathological le-
sions outside the motor system. Moreover it is clear that non-neuronal
cells play an important role in disease as well. Hence the apparent
motor neuron speciﬁcity of ALS-associated insults such as transport def-
icits is relative.
Another important question is whether restoring axonal transport is
sufﬁcient to cure neurodegenerative diseases. In case of transport de-
fects caused bymutations in the axonal transportmachinery the answer
to that question is probably yes and maybe gene therapy holds the fu-
ture for those cases. In other cases, the answer is less clear-cut. It
seems most likely that restoring axonal transport will not be a magic
bullet treatment but will be of beneﬁt in combination with other treat-
ments targeting the diverse cellularmechanism associatedwith disease
such as protein aggregation and mitochondrial damage. Indeed, the
widespread and early nature of axonal transport defects in ALS suggests
that these defects will have to be addressed if treatment is to be effec-
tive. Further efforts to standardise the measurement and analysis of ax-
onal transport and to develop non-invasive methods to quantify axonal
transport in vivo in animal models and in patients, as well as further re-
search into the molecular mechanisms underlying axonal transport de-
fects will be needed if we are to develop and validate treatments that
target axonal transport.
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